M&A Activity • Apr 4, 2023
M&A Activity
Open in ViewerOpens in native device viewer
PRESS RELEASE
Montpellier, April 4, 2023 at 8:00 a.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company
developing drug candidates based on its proprietary technology for the administration of active ingredients in
nano micelles
PARTNER INTERNATIONAL provides services to companies in the pharmaceutical and biotechnology industries who wish to expand their markets internationally. Partner International's list of services includes strategic partners
The PARTNER INTERNATIONAL team has many years of experience in business and business development and can quickly identify potential licensing opportunities internationally. With more than 45,000 companies in their network, long history of transactions at all stages of development.
As part of the agreement with MEDESIS PHARMA scheduled for an initial period of 6 months renewable, PARTNER As part of the agreement with MEDESIS PHARMA scheduled for an Initial period of o months renewable, PARTINER
INTERNATIONAL will target key pharmaceutical companies with activity in the fields concerned by the preclinical a sources of funding.
To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).
This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.
Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.
French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 71 patents, the result of 17 years of research.
Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP
For more information: www.medesispharma.com
MEDESIS PHARMA Jean Claude Maurel Tel: +33 4 67 03 03 96 [email protected]
CALYPTUS Marie Calleux Tel: +33 1 53 65 68 66 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.